SENS-601 injected into the inner ear for children with GJB2-related hearing loss
Tests SENS-601 injected into the cochlea in children with GJB2-related hearing loss.
Key facts
- Who runs it
- Sensorion
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 18 people, planned
- Starts
- Jan 2027
- Expected to end
- Dec 2034
- Type of study
- Interventional, 3 groups
- Treatments tested
- SENS-601 administration
- Record updated
- 17 November 2026
Who can take part
- Age
- 6 months to 6 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Males or females aged ≥6 months to ≤6 years
- Congenital bilateral severe sensorineural hearing loss
- Biallelic GJB2 variation(s)
- Documented normal cochlea and internal auditory canals
Who cannot take part
- Have been dosed in a previous gene therapy clinical study
- Prior or current cochlear implant in the ear to be treated with SENS-601
- Contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk
- History of chronic, acute, or major disease
- Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in France.
- Hopital Necker Enfants MaladesParis, FranceTaking people
About the trial
What the trial wants to find out
This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.
The 3 groups in the trial
- Dose escalation - Dose Level 1Treatment being tested
Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system
Treatment: SENS-601 administration
- Dose escalation - Dose Level 2Treatment being tested
Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system
Treatment: SENS-601 administration
- Dose expansion groupTreatment being tested
Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase
Treatment: SENS-601 administration
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, A4, 1 to 2 pages. US Letter size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability
- Plain-language title
- SENS-601 injected into the inner ear for children with GJB2-related hearing lossGenerated from the registry record. The registry title is the official one.
- Criteria questions
- Built from NCT07941115, who can take part
- Record updated
- 17 November 2026